$BMY Headlines Merck hits a new high as analyst
Post# of 94146
Posted On: 01/31/2014 2:44:16 PM
$BMY Headlines
Merck hits a new high as analyst sees opening for new cancer drug 11:16 a.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 5:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 3:50 p.m. Jan. 24, 2014 - Sue Chang
U.S. stock futures trim losses ahead of market open 8:57 a.m. Jan. 24, 2014 - Barbara Kollmeyer
Beam, Honeywell, Procter & Gamble are stocks to watch 5:38 a.m. Jan. 24, 2014 - Sue Chang
AstraZeneca, Bristol-Myers Secure EU OK for Xigduo 2:44 a.m. Jan. 22, 2014 - MarketWatch.com
‘Sloppy’ market turns to consumer, tech earnings 8:01 a.m. Jan. 19, 2014 - Wallace Witkowski
America's best and most generous 401(k)s 2:30 p.m. Jan. 15, 2014 - Anne Tergesen
Merck initiates melanoma filing with FDA 11:45 a.m. Jan. 13, 2014 - Tess Stynes
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - Russ Britt
Not all pharmaceuticals are created equal 12:40 p.m. Dec. 26, 2013 - The Trading Deck
FTSE 100 rises, shaking off retail data after Fed taper 12:06 p.m. Dec. 19, 2013 - Sara Sjolin
European stocks rally on Fed taper, rate views 12:00 p.m. Dec. 19, 2013 - Sara Sjolin
AstraZeneca to buy Bristol-Myers diabetes-JV stake 3:25 a.m. Dec. 19, 2013 - MarketWatch.com
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - Russ Britt
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Nasdaq Composite rattles cage on the 4,000 mark 11:29 a.m. Nov. 25, 2013 - Michael Ashbaugh
S&P, Dow hold tightly to record territory 10:36 a.m. Nov. 4, 2013 - Michael Ashbaugh
J.C. Penney, Bristol-Myers top S&P 500 6:08 p.m. Oct. 28, 2013 - Saumya Vaishampayan
S&P up for 8th day in 9; Dow, Nasdaq flat 3:58 p.m. Oct. 28, 2013 - Victor Reklaitis
6 Reasons Why Bristol-Myers Is A Good Immuno-Oncology Investment For 2014 7:52 a.m. Today - Seeking Alpha
5 Stocks Pulling The Drugs Industry Downward 12:02 p.m. Jan. 29, 2014 - TheStreet.com
The Best of the Best Picks of the Credit Suisse Top 50 Stocks 8:09 a.m. Jan. 29, 2014 - 247WallSt.com
'Mad Money' Lightning Round: Sell, Sell, Sell Windstream 6:00 a.m. Jan. 29, 2014 - TheStreet.com
Cramer's Lightning Round - Agilent Is Sensational (1/28/14) 5:16 a.m. Jan. 29, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Where Have All the Sellers Gone? 8:34 p.m. Jan. 28, 2014 - TheStreet.com
Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised 10:22 a.m. Jan. 28, 2014 - TheStreet.com
Questcor 57% January Upside Eclipsed Healthcare Dogs 9:36 a.m. Jan. 28, 2014 - Seeking Alpha
The Acquisition Of Mills Pharmaceuticals Put Another Arrow In The Quiver Of Galena 6:07 p.m. Jan. 27, 2014 - Seeking Alpha
Bristol-Myers - Nivolumab's Delays Warrant Friday's Sell-Off 3:21 p.m. Jan. 27, 2014 - Seeking Alpha
One Factor Driving Bristol-Myers Squibb (BMY) Down Today 3:06 p.m. Jan. 27, 2014 - TheStreet.com
Merck +2.8% as Morgan Stanley sees opening for new cancer drug 12:32 p.m. Jan. 27, 2014 - Seeking Alpha
What A Surprise 12:46 a.m. Jan. 26, 2014 - Seeking Alpha
5 New Drugs That Could Be Blockbusters in 2014 3:42 a.m. Jan. 25, 2014 - Barrons.com
Focus On Cancer Immunotherapy Results 3:41 a.m. Jan. 25, 2014 - Seeking Alpha
Big Pharmas Battle For The Billion-Dollar Melanoma Market 6:42 p.m. Jan. 24, 2014 - Seeking Alpha
Bristol-Myers Squibb's CEO Discusses Q4 2013 Results - Earnings Call Transcript 2:49 p.m. Jan. 24, 2014 - Seeking Alpha
Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment 2:21 p.m. Jan. 24, 2014 - benzinga.com
Bristol Q4 Beats, But Nivolumab Still Worries Market 12:51 p.m. Jan. 24, 2014 - Investors Business Daily
BMY Pummeled After Earnings, But Bristol-Myers Squibb Stock Still a Buy 10:20 a.m. Jan. 24, 2014 - InvestorPlace.com
Critical Alerts For Facebook, News Corp, Bristol Myers, Akamai, and Total SA Released By InvestorsObserver 9:31 a.m. Today - PR Newswire - PRF
The American Cancer Society and Stand Up To Cancer Announce Collaborative Research Effort 9:00 a.m. Jan. 29, 2014 - PR Newswire - PRF
Sundia Appoints a New Board Advisor 8:00 a.m. Jan. 27, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results 7:30 a.m. Jan. 24, 2014 - BusinessWire - BZX
Theravance Appoints Frank Pasqualone Senior Vice President, Operations 4:05 p.m. Jan. 23, 2014 - Marketwire
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
Relyco Closes Out Successful 2013 and Kicks Off 25th Anniversary in 2014 10:05 a.m. Jan. 22, 2014 - Marketwire
Pharm-Bio Building Boom: More Than $20 Billion Set for 2014 North American Capital Project Starts, an Industrial Info News Alert 6:15 a.m. Jan. 17, 2014 - Marketwire
AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research Initiative 8:30 a.m. Jan. 16, 2014 - BusinessWire - BZX
Regulatory Updates, Management Changes, and Conference Calls - Research Report on Bristol-Myers Squibb, Amgen, St. Jude Medical, Boston Scientific, and Mylan 8:00 a.m. Jan. 15, 2014 - PR Newswire - PRF
RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase 5:00 a.m. Jan. 15, 2014 - BusinessWire - BZX
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis 8:00 a.m. Jan. 13, 2014 - GlobeNewswire
U.S. FDA Approves Farxiga™ (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes 2:02 a.m. Jan. 13, 2014 - BusinessWire - BZX
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors 9:00 a.m. Jan. 9, 2014 - PR Newswire
Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C 8:29 a.m. Jan. 9, 2014 - BusinessWire
Healthcare Companies Announce Drug Launches, Upcoming Conference Calls, and Financial Results Schedules - Research Report on Bristol-Myers Squibb, Teva, Jazz, AmerisourceBergen and Arena 8:00 a.m. Jan. 9, 2014 - PR Newswire
AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga(TM) (dapagliflozin) 5:05 p.m. Jan. 8, 2014 - BusinessWire
Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency 6:59 a.m. Jan. 8, 2014 - BusinessWire
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2013 on January 24 3:15 p.m. Jan. 6, 2014 - BusinessWire
Merck hits a new high as analyst sees opening for new cancer drug 11:16 a.m. Jan. 27, 2014 - Russ Britt
U.S. stocks tumble; Dow drops 318 points 5:29 p.m. Jan. 24, 2014 - Anora Mahmudova
Juniper buoyed by Jana stake; Herbalife loss grows 3:50 p.m. Jan. 24, 2014 - Sue Chang
U.S. stock futures trim losses ahead of market open 8:57 a.m. Jan. 24, 2014 - Barbara Kollmeyer
Beam, Honeywell, Procter & Gamble are stocks to watch 5:38 a.m. Jan. 24, 2014 - Sue Chang
AstraZeneca, Bristol-Myers Secure EU OK for Xigduo 2:44 a.m. Jan. 22, 2014 - MarketWatch.com
‘Sloppy’ market turns to consumer, tech earnings 8:01 a.m. Jan. 19, 2014 - Wallace Witkowski
America's best and most generous 401(k)s 2:30 p.m. Jan. 15, 2014 - Anne Tergesen
Merck initiates melanoma filing with FDA 11:45 a.m. Jan. 13, 2014 - Tess Stynes
Statin usefulness questioned, but patent expirations may ease pain 1:02 p.m. Jan. 8, 2014 - Russ Britt
Not all pharmaceuticals are created equal 12:40 p.m. Dec. 26, 2013 - The Trading Deck
FTSE 100 rises, shaking off retail data after Fed taper 12:06 p.m. Dec. 19, 2013 - Sara Sjolin
European stocks rally on Fed taper, rate views 12:00 p.m. Dec. 19, 2013 - Sara Sjolin
AstraZeneca to buy Bristol-Myers diabetes-JV stake 3:25 a.m. Dec. 19, 2013 - MarketWatch.com
Pfizer and Kaiser: They not only rhyme, they're in sync with workers 11:12 a.m. Dec. 10, 2013 - Russ Britt
Safe and steady ETFs for the new year 12:03 p.m. Dec. 9, 2013 - Jim Lowell
Nasdaq Composite rattles cage on the 4,000 mark 11:29 a.m. Nov. 25, 2013 - Michael Ashbaugh
S&P, Dow hold tightly to record territory 10:36 a.m. Nov. 4, 2013 - Michael Ashbaugh
J.C. Penney, Bristol-Myers top S&P 500 6:08 p.m. Oct. 28, 2013 - Saumya Vaishampayan
S&P up for 8th day in 9; Dow, Nasdaq flat 3:58 p.m. Oct. 28, 2013 - Victor Reklaitis
6 Reasons Why Bristol-Myers Is A Good Immuno-Oncology Investment For 2014 7:52 a.m. Today - Seeking Alpha
5 Stocks Pulling The Drugs Industry Downward 12:02 p.m. Jan. 29, 2014 - TheStreet.com
The Best of the Best Picks of the Credit Suisse Top 50 Stocks 8:09 a.m. Jan. 29, 2014 - 247WallSt.com
'Mad Money' Lightning Round: Sell, Sell, Sell Windstream 6:00 a.m. Jan. 29, 2014 - TheStreet.com
Cramer's Lightning Round - Agilent Is Sensational (1/28/14) 5:16 a.m. Jan. 29, 2014 - Seeking Alpha
Jim Cramer's 'Mad Money' Recap: Where Have All the Sellers Gone? 8:34 p.m. Jan. 28, 2014 - TheStreet.com
Idenix Pharma CEO Speaks On Plans for the $107 Million Just Raised 10:22 a.m. Jan. 28, 2014 - TheStreet.com
Questcor 57% January Upside Eclipsed Healthcare Dogs 9:36 a.m. Jan. 28, 2014 - Seeking Alpha
The Acquisition Of Mills Pharmaceuticals Put Another Arrow In The Quiver Of Galena 6:07 p.m. Jan. 27, 2014 - Seeking Alpha
Bristol-Myers - Nivolumab's Delays Warrant Friday's Sell-Off 3:21 p.m. Jan. 27, 2014 - Seeking Alpha
One Factor Driving Bristol-Myers Squibb (BMY) Down Today 3:06 p.m. Jan. 27, 2014 - TheStreet.com
Merck +2.8% as Morgan Stanley sees opening for new cancer drug 12:32 p.m. Jan. 27, 2014 - Seeking Alpha
What A Surprise 12:46 a.m. Jan. 26, 2014 - Seeking Alpha
5 New Drugs That Could Be Blockbusters in 2014 3:42 a.m. Jan. 25, 2014 - Barrons.com
Focus On Cancer Immunotherapy Results 3:41 a.m. Jan. 25, 2014 - Seeking Alpha
Big Pharmas Battle For The Billion-Dollar Melanoma Market 6:42 p.m. Jan. 24, 2014 - Seeking Alpha
Bristol-Myers Squibb's CEO Discusses Q4 2013 Results - Earnings Call Transcript 2:49 p.m. Jan. 24, 2014 - Seeking Alpha
Merck Shares Higher Following Bristol-Myers' Phase 3 Disappointment 2:21 p.m. Jan. 24, 2014 - benzinga.com
Bristol Q4 Beats, But Nivolumab Still Worries Market 12:51 p.m. Jan. 24, 2014 - Investors Business Daily
BMY Pummeled After Earnings, But Bristol-Myers Squibb Stock Still a Buy 10:20 a.m. Jan. 24, 2014 - InvestorPlace.com
Critical Alerts For Facebook, News Corp, Bristol Myers, Akamai, and Total SA Released By InvestorsObserver 9:31 a.m. Today - PR Newswire - PRF
The American Cancer Society and Stand Up To Cancer Announce Collaborative Research Effort 9:00 a.m. Jan. 29, 2014 - PR Newswire - PRF
Sundia Appoints a New Board Advisor 8:00 a.m. Jan. 27, 2014 - PR Newswire - PRF
Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results 7:30 a.m. Jan. 24, 2014 - BusinessWire - BZX
Theravance Appoints Frank Pasqualone Senior Vice President, Operations 4:05 p.m. Jan. 23, 2014 - Marketwire
Pharmerging Markets 2012-2016 11:12 a.m. Jan. 22, 2014 - PR Newswire - PRF
Relyco Closes Out Successful 2013 and Kicks Off 25th Anniversary in 2014 10:05 a.m. Jan. 22, 2014 - Marketwire
Pharm-Bio Building Boom: More Than $20 Billion Set for 2014 North American Capital Project Starts, an Industrial Info News Alert 6:15 a.m. Jan. 17, 2014 - Marketwire
AstraZeneca and Bristol-Myers Squibb Diabetes Alliance Provides $5 Million Grant for American Diabetes Association's Pathway to Stop Diabetes Research Initiative 8:30 a.m. Jan. 16, 2014 - BusinessWire - BZX
Regulatory Updates, Management Changes, and Conference Calls - Research Report on Bristol-Myers Squibb, Amgen, St. Jude Medical, Boston Scientific, and Mylan 8:00 a.m. Jan. 15, 2014 - PR Newswire - PRF
RBCC Partner Therakine Presents Novel Drug Delivery Technology at Biotech Showcase 5:00 a.m. Jan. 15, 2014 - BusinessWire - BZX
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis 8:00 a.m. Jan. 13, 2014 - GlobeNewswire
U.S. FDA Approves Farxiga™ (Dapagliflozin) Tablets for the Treatment of Adult Patients with Type 2 Diabetes 2:02 a.m. Jan. 13, 2014 - BusinessWire - BZX
Sorrento Therapeutics Welcomes William S. Marth as Chairman of the Board of Directors 9:00 a.m. Jan. 9, 2014 - PR Newswire
Vertex Announces Sustained Viral Response Rate (SVR4) Data from All-Oral Study of VX-135 in Combination with Daclatasvir in Hepatitis C 8:29 a.m. Jan. 9, 2014 - BusinessWire
Healthcare Companies Announce Drug Launches, Upcoming Conference Calls, and Financial Results Schedules - Research Report on Bristol-Myers Squibb, Teva, Jazz, AmerisourceBergen and Arena 8:00 a.m. Jan. 9, 2014 - PR Newswire
AstraZeneca and Bristol-Myers Squibb Announce U.S. FDA Approval of Farxiga(TM) (dapagliflozin) 5:05 p.m. Jan. 8, 2014 - BusinessWire
Daclatasvir Marketing Authorization Application for Treatment of Chronic Hepatitis C Validated for Accelerated Regulatory Review by the European Medicines Agency 6:59 a.m. Jan. 8, 2014 - BusinessWire
Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan 8:00 a.m. Jan. 7, 2014 - PR Newswire
Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2013 on January 24 3:15 p.m. Jan. 6, 2014 - BusinessWire
(0)
(0)Scroll down for more posts ▼